These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7777671)

  • 41. Sotalol in patients with implanted automatic defibrillators: effects on defibrillation and comparison with amiodarone.
    Dorian P; Newman D; Harris L; Downar E
    Can J Cardiol; 1994 Mar; 10(2):193-200. PubMed ID: 8143220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
    Leibowitz D
    J Clin Pharmacol; 1993 Jun; 33(6):508-12. PubMed ID: 8366175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of sotalol for life-threatening ventricular arrhythmias.
    Roden DM
    Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.
    Hohnloser SH; Zabel M; Krause T; Just H
    Am Heart J; 1992 May; 123(5):1220-4. PubMed ID: 1575137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sotalol: a beta blocker with unique antiarrhythmic properties.
    Singh BN; Nademanee K
    Am Heart J; 1987 Jul; 114(1 Pt 1):121-39. PubMed ID: 3300230
    [No Abstract]   [Full Text] [Related]  

  • 47. Electrophysiologic and antiarrhythmic effects of D-sotalol.
    Brachmann J; Beyer T; Schmitt C; Schöls W; Montero M; Hilbel T; Schweizer M; Kübler W
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S91-5. PubMed ID: 1279315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Electrophysiologic properties of sotalol and d-sotalol. A current view.
    Touboul P
    Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
    Hohnloser SH; Meinertz T; Stubbs P; Crijns HJ; Blanc JJ; Rizzon P; Cheuvart B
    Circulation; 1995 Sep; 92(6):1517-25. PubMed ID: 7664435
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias.
    Anastasiou-Nana MI; Gilbert EM; Miller RH; Singh S; Freedman RA; Keefe DL; Saksena S; MacNeil DJ; Anderson JL
    Am J Cardiol; 1991 Mar; 67(6):511-6. PubMed ID: 1705386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sotalol in Life-Threatening Ventricular Arrhythmias: A Unique Class III Antiarrhythmic. Symposium proceedings. Phoenix, Arizona, September 19-22, 1991.
    Am J Cardiol; 1993 Aug; 72(4):1A-85A. PubMed ID: 8102220
    [No Abstract]   [Full Text] [Related]  

  • 54. Sotalol versus class I and II antiarrhythmic agents.
    Hanyok JJ; MacNeil DJ
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():603-11. PubMed ID: 2275890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring.
    Reiffel JA; Hahn E; Hartz V; Reiter MJ
    Am J Cardiol; 1997 Apr; 79(8):1048-53. PubMed ID: 9114762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
    Anderson JL
    J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of sotalol on exercise-induced ventricular arrhythmias.
    Petzl DH; Probst P; Glogar D; Schuster E
    Eur Heart J; 1988 Mar; 9(3):265-70. PubMed ID: 3383867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias.
    Lee RJ; Wong M; Siu A; Namekawa-Wong M; Epstein LM; Fitzpatrick AP; Grogin HR; Scheinman MM; Lesh MD
    Am Heart J; 1996 Nov; 132(5):973-8. PubMed ID: 8892770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Electrophysiological effects of sotalol--just another beta blocker?
    Nathan AW; Hellestrand KJ; Bexton RS; Ward DE; Spurrell RA; Camm AJ
    Br Heart J; 1982 Jun; 47(6):515-20. PubMed ID: 7082499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.